Limited Offer
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Manual of Hematopoietic Cell Transplantation and Cellular Therapies
- 1st Edition - December 23, 2022
- Editors: Qaiser Bashir, Elizabeth J. Shpall, Richard E. Champlin
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 7 9 8 3 3 - 4
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 8 4 2 3 - 6
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 7 9 8 3 4 - 1
Led by authors from MD Anderson’s Stem Cell Transplantation and Cellular Therapy Department, the world’s largest and highly respected program at the forefront of rapidly advancing… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteLed by authors from MD Anderson’s Stem Cell Transplantation and Cellular Therapy Department, the world’s largest and highly respected program at the forefront of rapidly advancing treatments in the field, Manual of Hematopoietic Cell Transplantation and Cellular Therapies is a comprehensive, focused reference covering the latest clinical developments and applications of stem cell transplant and cellular therapies for hematologic malignancies and solid tumors. This cutting-edge title, with a majority contribution from the MD Anderson Cancer Center and leading faculty from other academic institutions, covers breakthrough cell-based therapies for various diseases including lymphoma, multiple myeloma, leukemia, and select solid tumor and autoimmune diseases. This unique, definitive resource is essential for hematologists, fellows in hematology and immunotherapy, mid-level providers, pharmacists, and oncologists who refer patients for cell-based therapies.
-
Addresses hematologic conditions including leukemia, lymphoma, and myeloma.
-
Offers guidance on hematopoietic cell transplantation for solid tumors.
-
Covers basic science principles, clinical aspects, pharmacology, radiation therapy, and disease-specific guidelines, including prevention and management of complications.
-
Discusses key topics such as hematopoietic cell collection, bone marrow harvesting, umbilical cord blood transplantation, CAR T-cell therapy, and patient/donor selection and preparation of HCT.
-
Features extensive summary boxes, bulleted content, and algorithms throughout for quick and easy reference.
-
Offers team-based, clinically-focused coverage from world-renowned leaders in the field.
-
An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud.
Fellows in hematology and immunotherapy (new), practicing hematologists and medical oncologists
- Cover image
- Title page
- Table of Contents
- Any screen, Any time, Anywhere
- Copyright
- List of Contributors
- Preface
- Part I: Introduction and Biological Aspects
- 1. Hematopoietic Transplantation: Past, Present, and Future
- The Past—Determination of the Fundamental Principles of Hematopoietic Cell Transplantation and Initial Clinical Experience
- The Present—Current Concepts and Practice of Hematopoietic Cell Transplantation
- The Future of Hematopoietic Cell Transplantation
- Conclusion
- References
- 2. Role of the Human Leukocyte Antigen System in Hematopoietic Stem Cell Transplantation
- Abstract
- Introduction
- Histocompatibility Testing in Support of Hematopoietic Stem Cell Transplantation
- Impact of HLA on Clinical Outcomes in HCT
- HLA Molecular Mismatch
- Summary
- Acknowledgments
- References
- Part II: Methodology
- 3. Hematopoietic Cell Collection
- Abstract
- Introduction
- Hematopoietic Stem Cells
- Graft Sources
- Graft Source Comparisons
- Graft Manipulation
- Cryopreservation
- References
- 4. Bayesian Statistical Methods in Stem Cell Transplantation and Cellular Therapy
- Abstract
- Elements of Bayesian Statistics
- Monitoring in a Single-Arm Trial of CTLs for Viruses Due to Immunosuppression
- Optimizing CAR-T Cell Dose for Hematologic Malignancies Using Efficacy-Toxicity Trade-Offs
- A Randomized Pilot Study of T-reg Cells for COVID-19–Induced Acute Respiratory Distress Syndrome
- Bayesian Sensitivity Analysis of Confounded Treatment-Institution Effects in Allo-HCT
- Estimating Effects on Survival of Antigens in Convalescent Plasma for Treating COVID-19
- A Precision Pharmacokinetic-Guided Dosing Algorithm for IV-Busulfan in Allo-HCT
- Acknowledgments
- References
- Part III: General Clinical Aspects
- 5. Patient and Donor Assessments in Preparation for Transplant
- Abstract
- Introduction
- Disease and Patient Assessments
- Donor Assessment
- Summary
- References
- 6. Transfusion Support During Hematopoietic Cell Transplantation
- Abstract
- Red Blood Cell Concentrates
- Platelet Concentrates
- Granulocytes Transfusions
- Fresh Frozen Plasma, Cryoprecipitate, and Fibrinogen
- Peritransplant Consideration
- Transfusion-Related Complications
- Conclusions
- Vascular Access in Hematopoietic Cell Transplantation
- Types of Central Venous Catheters and Materials Used
- Venous Access
- Complications
- Catheters for Leukapheresis
- Conclusions
- Nutrition, Cachexia, and Clinical Applications in Hematopoietic Cell Transplantation
- Pathophysiology
- Assessment and Appropriate Screening
- Primary Screening
- Nutritional Requirements for Hematopoietic Cell Transplant Recipients
- Artificial Nutritional Interventions
- Recommended Diet
- Treatments to Stimulate Appetite
- Conclusions
- References
- 7. Haploidentical Hematopoietic Cell Transplantation
- Abstract
- Introduction
- Evolution of Haploidentical Hematopoietic Cell Transplantation
- Modern Methods of Haploidentical Transplantation
- Potential Complications After Haploidentical Hematopoietic Cell Transplantation (Box 7.2)
- Donor Selection for Haploidentical Hematopoietic Cell Transplantation
- Future Directions
- References
- 8. Umbilical Cord Blood Transplantation
- Abstract
- Introduction
- Comparison of Cord Blood to Other Graft Sources
- Cord Blood Unit Selection
- Conditioning Regimens
- GVHD Prophylaxis
- Infection Prophylaxis and Monitoring
- Cord Blood Transplantation Complications
- Major Developments in Cord Blood Transplantation
- Conclusion
- References
- 9. Process and General Management of Patients Undergoing Chimeric Antigen Receptor Therapies
- Abstract
- Introduction
- Lymphodepleting Conditioning
- Product Receipt and Processing
- CAR T-Cell Product Infusion
- Postinfusion Monitoring
- Conclusion
- References
- Part IV: Pharmacology and Radiation Therapy
- 10. Preparative Regimens Used in Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapies
- Abstract
- Hematopoietic Cell Transplant Preparative Regimens
- Preparative Regimen Intensity
- Total Body Irradiation
- Radioisotopes and Radioimmunotherapy
- Alkylating Agents
- Topoisomerase II Inhibitors
- Platinum Agents
- Taxane Derivatives
- Monoclonal Antibodies
- Polyclonal Antibodies
- References
- 11. Pharmacology of Drugs Used in Hematopoietic Cell Transplant and Chimeric Antigen Receptor Therapies
- Abstract
- Introduction
- Antimicrobial Agents
- Antibacterial
- Antifungal
- Antiviral
- Immunosuppressants
- Graft-Versus-Host Disease Agents: Prevention
- Graft-Versus-Host Disease Agents: Treatment
- References
- 12. Radiobiologic Principles and the Role of Radiotherapy in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy
- Abstract
- Introduction
- Radiobiology
- Radiotherapy in the Setting of Hematopoietic Cell Transplantation
- Role of Radiation in Chimeric Antigen Receptor T-Cell Therapy
- Radiation and Chimeric Antigen Receptor T-Cell Therapy
- Radiotherapy Timing, Target, and Dose
- Conclusion
- References
- Part V: Disease-Specific Indications and Results
- 13. Hematopoietic Cell Transplantation in Adult With Acute Myeloid Leukemia
- Abstract
- Introduction
- Current Trends
- Current Results
- Best Postremission Therapy—Do We Know the Answer?
- Donor and Graft Selection
- Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Acute Myeloid Leukemia
- Conditioning Regimen in Acute Myeloid Leukemia
- Prevention of Relapse After Allogeneic Transplant
- Relapse After Allogeneic Hematopoietic Cell Transplantation
- Timing of Transplant in Acute Promyelocytic Leukemia
- Future Perspective
- References
- 14. Chimeric Antigen Receptor Therapy in Acute Myeloid Leukemia
- Abstract
- Brief Overview of Acute Myeloid Leukemia
- Brief Overview of the Success of Chimeric Antigen Receptor Therapy
- Antigenic Targets for Chimeric Antigen Receptor Therapy in Acute Myeloid Leukemia
- Chimeric Antigen Receptor–Natural Killer Therapy in Acute Myeloid Leukemia
- Chimeric Antigen Receptor-Gamma-Delta Therapy in Acute Myeloid Leukemia
- Chimeric Antigen Receptor–Related Toxicity
- Innovative Therapies
- Conclusion
- References
- 15. Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia
- Abstract
- Introduction
- Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia Poststandard Chemotherapy
- Hematopoietic Cell Transplantation Conditioning Strategies in Acute Lymphoblastic Leukemia
- Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia After Targeted Cellular Therapy
- Alternative Donor Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia
- Conclusion
- Acknowledgments
- References
- 16. Chimeric Antigen Receptor T-Cell Therapy in Acute Lymphoblastic Leukemia
- Abstract
- Introduction
- Chimeric Antigen Receptor T-Cell therapy or Production
- Chimeric Antigen Receptor T-Cell Administration
- Chimeric Antigen Receptor T-Cell Toxicities
- Autologous Chimeric Antigen Receptor T-Cell Therapy
- Chimeric Antigen Receptor T-Cells for Central Nervous System Diseases
- Allogeneic Chimeric Antigen Receptor T-Cell Therapy
- Conclusions
- References
- 17. Hematopoietic Cell Transplantation and Other Cellular Therapies for Chronic Lymphocytic Leukemia
- Abstract
- Background
- Prognostic Markers in Chronic Lymphocytic Leukemia
- Risk Stratification of Chronic Lymphocytic Leukemia in the Setting of Hematopoietic Cell Transplant
- Impact of Novel Agents on Chronic Lymphocytic Leukemia Management
- Autologous Hematopoietic Cell Transplantation—Historical Experience
- Allogeneic Hematopoietic Cell Transplantation
- Myeloablative Regimens (Table 17.3)
- Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation (Table 17.4)
- Role of Donor Lymphocyte Infusion
- Minimal Residual Disease—Methods of Monitoring and Significance
- Summary of Factors Predicting Allogeneic Hematopoietic Cell Transplantation Outcomes
- Donor Selection for Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia: Special Considerations
- Alternative Donor Allogeneic Hematopoietic Cell Transplantation
- Other Adaptive Cellular Therapies for Chronic Lymphocytic Leukemia
- Allogeneic Hematopoietic Cell Transplantation in the Era of Novel Agents
- Richter’s Transformation
- Treatment of Posttransplant Relapse
- Resistance Mechanisms to Chimeric Antigen Receptor T-Cell Therapy and the Graft-Versus-Leukemia Effect After Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia
- Conclusions and Future Directions
- References
- 18. Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome Patients
- Abstract
- Key Concepts
- Background
- Who Will Benefit from Allogeneic Hematopoietic Cell Transplant?
- Choosing the Optimal Time Point of Hematopoietic Cell Transplant in Myelodysplastic Syndromes
- Cytoreduction Before Allogeneic Hematopoietic Cell Transplant
- Age and Comorbidity
- Conditioning Intensity
- Donor Selection
- Prevention of Relapse
- Conclusions
- References
- 19. Allogeneic Cell Transplantation for Myeloproliferative Neoplasms
- Abstract
- Introduction
- Staging and Prognostic Factors
- Summary
- References
- 20. Hematopoietic Cell Transplantation in Aplastic Anemia
- Abstract
- Discussion
- Transplant Considerations When Matched Related or Unrelated Donors are Unavailable
- Factors that have Improved Posttransplant Outcomes in Severe Aplastic Anemia
- Conditioning Regimens for Hematopoietic Cell Transplantation Associated With Favorable Outcomes in Severe Aplastic Anemia
- Points to Consider When Planning a Hematopoietic Cell Transplantation for Severe Aplastic Anemia
- Summary of Hematopoietic Cell Transplant Recommendations Based on Severe Aplastic Anemia Patient Age
- References
- 21. Hematopoietic Cell Transplantation in Multiple Myeloma
- Abstract
- Introduction
- Eligibility for Autologous Hematopoietic Cell Transplant
- Autologous Hematopoietic Cell Transplant Versus Nontransplant Approaches
- Single Versus Tandem Autologous Hematopoietic Cell Transplant
- Early Versus Delayed Autologous Hematopoietic Cell Transplant
- Autologous Hematopoietic Cell Transplant in Relapsed Disease
- Improving the Conditioning Regimen
- Autologous Hematopoietic Cell Transplant in the Era of Novel Therapies: Integration Into Induction, Consolidation, and Maintenance
- Allogeneic Hematopoietic Cell Transplant in the Upfront Setting
- Allogeneic Hematopoietic Cell Transplant in Relapsed Disease
- References
- 22. Chimeric Antigen Receptor Therapy in Multiple Myeloma
- Abstract
- Introduction
- B-Cell Maturation Antigen Biology and Rationale for Selection as Chimeric Antigen Receptor T-Cell Target Antigen
- Case Vignette
- Autologous Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapies
- Unique Aspects of Toxicity With Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy
- Mechanisms of Resistance to Treatment With Autologous Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy and Strategies for Overcoming Them
- Allogeneic Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy
- Chimeric Antigen Receptor T-Cell Therapies Targeting Antigens Other Than B-Cell Maturation Antigen
- Conclusions and Future Directions
- References
- 23. Hematopoietic Cell Transplantation in Light Chain Amyloidosis
- Abstract
- Introduction
- Patient Selection
- Hematopoietic Cell Transplant
- Posttransplant Management
- Future Directions
- References
- 24. Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma
- Abstract
- Introduction
- Non-Hodgkin Lymphoma Classification
- Summary
- References
- 25. Hematopoietic Cell Transplantation for Hodgkin Lymphoma
- Abstract
- Role of Autologous Hematopoietic Cell Transplantation in Hodgkin Lymphoma
- Factors that Predict Recurrence After Transplant
- Objectives of Salvage Chemotherapy Before Transplant
- Impact of Conditioning Regimen
- Poor-Risk Hodgkin Lymphoma and Autologous Transplant
- Indications for Peritransplant Radiation
- Posttransplant Maintenance
- Allogeneic Hematopoietic Transplantation in Hodgkin Lymphoma
- Myeloablative Versus Reduced Intensity Conditioning Regimens for Hodgkin Lymphoma
- Alternative Donor Allogeneic Transplantation in Hodgkin Lymphoma
- Use of Donor Lymphocyte Infusions in Hodgkin Lymphoma
- Complications Associated With Transplantation Specific to Hodgkin Lymphoma
- References
- 26. Chimeric Antigen Receptor Therapy in Lymphoma
- Abstract
- Introduction
- ZUMA-1: Axi-Cel for Relapsed/Refractory Aggressive Large B-Cell Lymphoma
- JULIET: Tisa-Cel for Relapsed/Refractory Large B-Cell Lymphoma
- TRANSCEND: Liso-Cel Relapsed/Refractory Large B-Cell Lymphoma
- ZUMA-2: Brexu-Cel for Relapsed/Refractory Mantle Cell Lymphoma
- ZUMA-5: Axi-Cel for Relapsed/Refractory Follicular Lymphoma
- Next Frontier
- Patient Selection
- Recommendations
- References
- 27. Hematopoietic Cell Transplantation in Rare Hematologic Malignancies
- Abstract
- Introduction
- Adult T-Cell Leukemia/Lymphoma
- Natural Killer/T-Cell Lymphomas
- Hepatosplenic T-Cell Lymphoma
- Subcutaneous Panniculitis T-Cell Lymphoma
- Langerhans Cell Histiocytosis
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Histiocytic Sarcoma
- References
- 28. Hematopoietic Cell Transplantation for Germ-Cell Tumors and Other Adult Solid Tumors
- Abstract
- Introduction to Germ-Cell Tumors
- Clinical Results in Refractory or Relapsed Nonseminomatous Germ-Cell Tumor
- Clinical Results in Front-Line High-Risk Nonseminomatous Germ-Cell Tumor
- Predictive Models of Outcome for Patients With Relapsed Germ-Cell Tumor Receiving High-Dose Chemotherapy
- High-Dose Chemotherapy for Germ-Cell Tumor Recommendations
- High-Dose Chemotherapy in High-Risk Breast Cancer
- Metastatic Breast Cancer
- Autologous Transplantation in Other Solid Tumors
- Allogeneic Hematopoietic Cell Transplantation for Solid Tumors
- Conclusions
- References
- 29. Natural Killer Cells: A Promising Cellular Therapy Platform to Conquer Cancer
- Abstract
- Background: Natural Killer Cell Biology
- Mechanisms of Natural Killer Cell Cytotoxicity
- Role of Natural Killer Cells in Tumor Surveillance
- Sources of Natural Killer Cells for Immunotherapy
- Strategies to Enhance Natural Killer Cell Function and Overcome Their Limitations
- Conclusion
- References
- Part VI: Prevention and Management of Complications
- 30. Infection Control, Prophylaxis, and Vaccinations in Hematopoietic Cell Transplantation Recipients
- Abstract
- Overview
- Infection Control Strategies Within Healthcare Facilities
- Preventive Practices for Relevant Infections in Hematopoietic Cell Transplant Recipients
- Preventive Measures to Reduce Infection Risk
- Pneumocystis Prophylaxis
- Toxoplasma gondii Prophylaxis
- Tuberculosis Prophylaxis
- Strongyloides Prophylaxis
- Immunizations
- References
- 31. Management of Infections in Stem Cell Transplant Recipients
- Abstract
- Most Common Infections After Hematopoietic Cell Transplant
- References
- 32. Graft Failure After Hematopoietic Cell Transplantation
- Abstract
- Introduction and Historical Perspective
- Concepts and Definitions
- Evaluation of Engraftment
- Biology of Engraftment
- Risk Factors for Graft Failure
- Causes of Graft Failure
- Incidence
- Approach to the Patient With Graft Failure
- Conclusion
- References
- 33. Graft-Versus-Host Disease
- Abstract
- Introduction
- Risk Factors of Graft-Versus-Host Disease
- Pathophysiology of Graft-Versus-Host Disease
- Classification of Graft-Versus-Host Disease
- Overlap Graft-Versus-Host Disease
- Graft-Versus-Host Disease Prophylaxis
- Mycophenolate Mofetil
- Antithymocyte Globulin for in Vivo T-Cell Depletion
- Posttransplantation Cyclophosphamide
- Comparison of Posttransplantation Cyclophosphamide and Antithymocyte Globulin–Based Graft-Versus-Host Disease Prevention Strategies
- Sirolimus
- Ex Vivo T-Cell Depletion for Graft-Versus-Host Disease Prophylaxis
- Future Directions and Novel Approaches to Prevent Graft-Versus-Host Disease
- Targeting Danger-Associated Molecular Patterns
- Kinase Inhibitors
- Monoclonal Antibodies Targeting Integrins
- Graft Manipulation Strategies Other Than T-Cell Depletion
- Adoptive Cell Therapy for Graft-Versus-Host Disease Prevention
- Intestinal Microbiome/Fecal Microbiota Transplant
- Other Novel Strategies in the Preclinical Phase
- Treatment of Graft-Versus-Host Disease
- Conclusions
- References
- 34. Miscellaneous Complications of Hematopoietic Cellular Transplantation
- Abstract
- Introduction
- Prehematologic Cell Transplantation Risk Factors for Toxicity
- Recipient Medical Clearance
- Preparative Regimen and Toxicities
- Infusion-Related Toxicities
- Sinusoidal Obstructive Syndrome
- Transplant-Associated Thrombotic Microangiopathy
- Thrombotic Thrombocytopenic Purpura
- Mucositis
- Malnutrition
- Preengraftment and Engraftment Syndrome
- Cytokine Release Syndrome
- Acute Kidney Injury
- Acute Respiratory Failure
- Posttransplant Lymphoproliferative Disease
- Hemorrhagic Cystitis
- Endocrine
- Fertility
- Neurologic
- Psychosocial Considerations
- References
- 35. Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy
- Abstract
- Introduction
- Rates of Cytokine Release Syndrome in Clinical Trials
- Kinetics of Cytokine Release Syndrome
- Chimeric Antigen Receptor Construct Components Influence on Cytokine Release Syndrome
- Cytokine Release Syndrome Rates inReal-World Data
- Cytokine Release Syndrome Pathogenesis
- Preclinical Models of Cytokine Release Syndrome
- Diagnosis and Grading of Cytokine Release Syndrome
- Management of Cytokine Release Syndrome
- Treatment of Cytokine Release Syndrome
- Secondary Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome
- Summary and Future Directions
- References
- 36. Neurologic Complications of Chimeric Antigen Receptor Therapy
- Abstract
- Epidemiology and Pathogenesis
- Clinical Presentation and Assessment
- Evaluation
- Treatment
- Summary of Treatment Principles
- Summary
- References
- 37. Miscellaneous Complications of Chimeric Antigen Receptor T-Cell Therapy
- Abstract
- Hemophagocytic Lymphohistiocytosis
- Graft-Versus-Host Disease
- Cytopenia
- B-Cell Aplasia, Hypogammaglobulinemia, and Infections
- Long-Term Neurologic, Cognitive, and Psychiatric Complications
- Organ-Specific Complications
- References
- 38. Symptom Management and Palliative Care in Hematologic Malignancies
- Abstract
- Introduction
- Quality-of-Life Measures
- Graft-Versus-Host Disease
- Mucositis
- Nausea and Vomiting
- Pain
- Mechanisms of Pain
- Pain Assessment
- Selecting a Pain Regimen
- Patient-Controlled Analgesia Among Hospitalized Patients
- Delirium
- Diarrhea
- Palliative Care in Hematopoietic Cell Transplantation
- Spiritual Care for Patients and Their Caregivers
- References
- 39. Survivorship
- Abstract
- Clinical Scenario
- Hematopoietic Cell Transplant Survivorship Care
- Psychosocial Late Effects
- References
- Index
- Confidence is ClinicalKey
- No. of pages: 608
- Language: English
- Edition: 1
- Published: December 23, 2022
- Imprint: Elsevier
- Hardback ISBN: 9780323798334
- eBook ISBN: 9780443284236
- eBook ISBN: 9780323798341
QB
Qaiser Bashir
Affiliations and expertise
Associate Professor of Medicine, Department of Stem Cell Transplantation & Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TexasES
Elizabeth J. Shpall
Affiliations and expertise
Professor and Chair, at interim, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine
Director, Cell Therapy Laboratory, Director, Cord Blood Bank, The University of Texas MD Anderson Cancer Center, Houston, TexasRC
Richard E. Champlin
Affiliations and expertise
Professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas